Metabolomic Profiling of Serum Biomarkers in Type 2 Diabetes Mellitus

Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder characterized by insulin resistance, impaired glucose metabolism, and an increased risk of cardiovascular and renal complications. Early and accurate biomarkers are crucial for diagnosis, monitoring disease progression, and evaluating therapeutic responses. Metabolomics, the comprehensive analysis of small molecule metabolites, has emerged as a powerful tool in understanding the pathophysiology of T2DM and identifying potential biomarkers for its diagnosis and management. This review explores the application of serum metabolomic profiling in T2DM, focusing on the identification and validation of metabolites that are altered in the disease state. We discuss key metabolic pathways involved in T2DM, including those related to glucose, lipid, amino acid, and nucleotide metabolism, and how these pathways are disrupted in the context of insulin resistance and beta-cell dysfunction. Specific serum biomarkers, such as branched-chain amino acids, acylcarnitines, and lipids, are highlighted for their potential use in predicting the onset of T2DM, monitoring disease progression, and assessing treatment efficacy. The review also examines the technologies used in metabolomic profiling, including gas chromatography-mass spectrometry (GC-MS), liquid chromatography-mass spectrometry (LC-MS), and nuclear magnetic resonance (NMR) spectroscopy, and their applications in large-scale epidemiological studies and clinical practice. We also discuss the challenges and limitations of metabolomic approaches, such as the need for standardization and the complexity of data interpretation. Finally, we explore the potential of integrating metabolomics with other «omics» technologies, such as genomics and proteomics, to provide a more holistic understanding of T2DM and pave the way for personalized medicine strategies.